A Southwest Oncology Group perspective on the Revised European-American Lymphoma classification

Gastric Mucosa-associated Lymphoid Tissue Lymphoma: An Important Differential Diagnosis for a Rapidly Growing Gastric Subepithelial Tumor - A Case Report and Literature Review

Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade lymphoma with a long median survival time because of its low proliferation rate. A 75-year-old man was referred to the hospital for hematemesis. Upper endoscopy revealed a 30-mm subepithelial tumor (SET). Abdominal CT and EUS revealed a homogeneously hypoechoic lesion arising from the second layer of the stomach, without distant metastasis. Laparoscopic wedge resection was performed. On microscopic examination, the tumor showed diffuse aggregation of small lymphoid cells with abnormal architecture. Neoplastic cells showed positive reactivity for CD20 and prominent lymphoepithelial lesions were observed. The urease breath test was also conducted, with a negative result. Our final diagnosis was <i>Helicobacter pylori</i>-negative MALT lymphoma (Ann Arbor classification I_E2), which is a rapidly growing SET pattern. This case highlights the importance of including gastric MALT lymphoma as a differential diagnosis for rapidly growing gastric SETs.

Diagnostic difficulties and treatment of non-Hodgkin lymphoma of the orbit

BACKGROUND

There are problems connected with the diagnosis of non-Hodgkin lymphomas of the orbit, before deciding on the correct treatment.

MATERIAL AND METHODS

Six out of 22 patients with a tumour of the orbit were treated between 1995 and 2004 for orbital non-Hodgkin lymphomas (NHL). Morphological-functional and aesthetic complications regarding the eyes, the delay between onset and diagnosing the disease and concomitant conditions were evaluated. Management was always tailored individually for each patient, depending on tumour location in the orbit. Surgical procedures comprised total or subtotal removal of the tumour via a semi-coronal access and lateral orbitotomy. Histological diagnosis of the tumours was made from the surgical specimens.

RESULTS

According to the REAL classification, 3 patients had a B-cell lymphoma from the MALT system with low malignancy, 2 other patients a diffuse B cell NHL and 1 patient a lymphoma from the germinal centre with intermediate malignancy. All patients had received chemotherapy. A 9-year remission was achieved in one, an 8-year in another and a 7-year remission in two more out of the total of 6 patients; one is living without relapse for 6 years. The last patient, in whom the lymphoma was diagnosed at the age of 70 years, died 4 years after the procedure without relapse due to cardiovascular and respiratory insufficiency.

CONCLUSIONS

Although the treatment of choice of NHL is chemotherapy, it is felt necessary to remove the whole or possibly the major part of the tumour in case of retrobulbar location when the histological subtype is unknown prior to surgery. However, the optic nerve should always been left intact, even when such tumour encircles this cranial nerve. Only sufficient biopsy material allows determination of the lymphoma subtype and selection of appropriate chemotherapy.

MCL-1 expression in B-cell non-Hodgkin’s lymphomas

B-cell non-Hodgkin's lymphomas are known to express BCL-2 family proteins, of which the myeloid cell leukemia-1 (MCL-1) protein is a member. MCL-1 is involved in viability and immortalization of normal and neoplastic B cells, and expression is regulated transcriptionally and posttranscriptionally, resulting in an anti-apoptotic (full length) or a pro-apoptotic (short isoform) gene product. In this study, we assessed 151 B-cell lymphomas for MCL-1 expression and analyzed for expression of the full-length and short isoforms of MCL-1 in B-cell lymphoma cell lines. By using immunohistochemistry, a subset of neoplasms in 9 lymphoma types studied expressed MCL-1, but expression was more frequent and intense in high-grade (43 of 49, 88%) compared with low-grade (34 of 92, 37%) lymphomas (P < 0.0001). In follicular lymphomas, MCL-1 expression positively correlated with increasing grade; 1 (14%) of eight grade 1, 7 (70%) of ten grade 2, and all 9 (100%) grade 3 were positive (P < 0.0008). All plasma cell myeloma cases assessed were also MCL-1 positive. By using Western blot analysis, 6 of 7 high-grade B-cell lymphoma cell lines showed predominant expression of full-length MCL-1, compared with no or weak expression of the short isoform. One myeloma and 1 of 2 mantle cell lymphoma cell lines also tested showed only full-length isoform expression. Our data suggest that MCL-1 is frequently expressed in high-grade B-cell lymphomas and plasma cell myeloma, most likely in its full-length isoform that is an active anti-apoptotic gene product. MCL-1 expression also correlates with grade and may contribute to transformation in follicular lymphomas.

Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: study of 116 cases

The bcl-2 family of proteins comprises both antagonists and agonists of apoptosis. We have investigated whether subsets of indolent B-cell non-Hodgkin's lymphoma (IB-NHL) differ in the expression of the bcl-2 family members; 116 cases of IB-NHL, composed of chronic lymphocytic leukemia (CLL, n = 48), follicular lymphoma (FL, n = 38), marginal zone B-cell lymphoma (MZBCL, n = 15), and mantle cell lymphoma (MCL, n = 15), were investigated for expression of bcl-2, bcl-X, mcl-1, bax, and bak proteins by immunohistochemistry. Expression of bcl-2 and bcl-X proteins was moderate/high among most IB-NHLs. Expression of mcl-1 was low/absent in most cases of CLL and MCL and low/moderate in most cases of FL and MZBCL. Most MCLs did not express bax protein. Bax expression was absent/low among most cases of CLL and low/moderate among most cases of FL and MZBCL. Expression of bak was moderate/low among most cases of CLL, MZBCL, and MCL but was absent/low among most cases of FL. The different subsets of IB-NHLs differ in their expression of mcl-1, bax, and bak proteins.

Lymphoma at the extremes of age

OBJECTIVES

To provide a review of the unique features of both Hodgkin's and non-Hodgkin's lymphoma in pediatric and geriatric patient populations. Treatment approaches and nursing care interventions at the extremes of age will be discussed.

DATA SOURCES

Review articles, research studies, and book chapters.

CONCLUSIONS

Lymphoma is a highly heterogeneous malignancy whose classification and management have undergone significant evolution. Of particular concern has been lymphoma's prevalence and treatment at the extremes of age. Appropriate treatment by age and subtype remains controversial.

IMPLICATIONS FOR NURSING PRACTICE

The nursing care of pediatric and geriatric patients with lymphoma presents numerous challenges in education, symptom management, and supportive care.